The Chart of the Day belongs to the gastrointestinal pharmaceutical products company Ironwood Pharmaceutical (IRWD) I found the stock by using Barchart's powerful screening functions to find stocks...
Ironwood's plan to purchase a smaller biotech should address some issues that have shareholders concerned.
Investors indicated approval of the company's upcoming $1 billion asset purchase.
A buyout offer by Ironwood Pharmaceuticals lifted the clinical-stage biotech's stock.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, presented findings during the 2023 Digestive Disease Week ® (DDW) meeting from a Phase III clinical trial on the potential...
Ironwood (IRWD) reports better-than-expected results, wherein both earnings and revenues beat estimates. The strong momentum of Linzess continues with 10% growth in prescription demand.